Unknown

Dataset Information

0

The Role of Biomarkers in the Management of Colorectal Liver Metastases.


ABSTRACT: Surgical management combined with improved systemic therapies have extended 5-year overall survival beyond 50% among patients with colorectal liver metastases (CRLM). Furthermore, a multitude of liver-directed therapies has improved local disease control for patients with unresectable CRLM. Unfortunately, a significant portion of patients treated with curative-intent hepatectomy develops disease recurrence. Traditional markers fail to risk-stratify and prognosticate patients with CRLM appropriately. Over the last few decades, advances in molecular sequencing technology have greatly expanded our knowledge of the pathophysiology and tumor microenvironment characteristics of CRLM. These investigations have revealed biomarkers with the potential to better inform management decisions in patients with CRLM. Actionable biomarkers such as RAS and BRAF mutations, microsatellite instability/mismatch repair status, and tumor mutational burden have been incorporated into national and societal guidelines. Other biomarkers, including circulating tumor DNA and radiomic features, are under active investigation to evaluate their clinical utility. Given the plethora of therapeutic modalities and lack of evidence on timing and sequence, reliable biomarkers are needed to assist clinicians with the development of patient-tailored management plans. In this review, we discuss the current evidence regarding biomarkers for patients with CRLM.

SUBMITTER: Hewitt DB 

PROVIDER: S-EPMC9559307 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

The Role of Biomarkers in the Management of Colorectal Liver Metastases.

Hewitt Daniel Brock DB   Brown Zachary J ZJ   Pawlik Timothy M TM  

Cancers 20220922 19


Surgical management combined with improved systemic therapies have extended 5-year overall survival beyond 50% among patients with colorectal liver metastases (CRLM). Furthermore, a multitude of liver-directed therapies has improved local disease control for patients with unresectable CRLM. Unfortunately, a significant portion of patients treated with curative-intent hepatectomy develops disease recurrence. Traditional markers fail to risk-stratify and prognosticate patients with CRLM appropriat  ...[more]

Similar Datasets

| S-EPMC8716993 | biostudies-literature
| S-EPMC7643190 | biostudies-literature
| S-EPMC8002956 | biostudies-literature
| PRJEB35154 | ENA
| S-EPMC7279011 | biostudies-literature
| S-EPMC8371911 | biostudies-literature
| S-EPMC8618941 | biostudies-literature
| S-EPMC11534783 | biostudies-literature
| S-EPMC8622404 | biostudies-literature
| S-EPMC5829437 | biostudies-literature